Institute for Stem Cell Science and Regenerative Medicine

Mission Bio and Abiosciences Partner to Co-develop Bioinformatics for Clinical Research Applications in China

Retrieved on: 
Wednesday, December 28, 2022
Tao, Mortality, City, Patient, Cell, Leukemia, Neoplasm, SAN, Biotechnology, Mining, Health, Gene, Partnership, AI, Institute for Stem Cell Science and Regenerative Medicine, Diagnosis, B cell, Clinical trial, Hospital, DNA, Mayfield (company), Disease resistance, Multimedia, Hematological Cancer Research Investment and Education Act, Biomarker, Therapy, Agilent Technologies, Algorithm, HIV disease progression rates, Doctor of Philosophy, Society, Memorial Sloan Kettering Cancer Center, ASH, MRD, Cancer, Summit, Disease, Vaccine, Pharmaceutical industry, Medical device, Science

SOUTH SAN FRANCISCO, Calif., Dec. 28, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers. The goal is to combine Mission Bio's industry-leading single-cell DNA and multi-omics capabilities with Abiosciences' cutting-edge artificial intelligence expertise, to uncover new disease signatures and address therapeutic resistance. These new capabilities can be leveraged in patient stratification for clinical trials and potentially, as a companion diagnostic tool.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 28, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers.
  • These new capabilities can be leveraged in patient stratification for clinical trials and potentially, as a companion diagnostic tool.
  • Mission Bio's Tapestri® Platform is a powerful tool that has been adopted increasingly for translational research and clinical trials, both at biopharma companies and in academia.
  • Mission Bio will support Abiosciences with its unique Tapestri single-cell multi-omics platform, custom panels, subject matter experts, and R&D expertise.

Small Pharma Shares Business Update Ahead of Annual Financial Results

Retrieved on: 
Wednesday, May 25, 2022
SSRI, Knowledge, MDD, COO, IM, Institute for Stem Cell Science and Regenerative Medicine, 30 Minutes, Government, Pharmacokinetics, Pfizer, Psychotherapy, Stem cell, Data, London Stock Exchange, GE Healthcare, LLC, University, Plant, J&J, TSX Venture Exchange, Phase, Small, Clinical trial, COVID-19, Marketing, Depression, Patent, CMC, Brain, Mammal, Tryptamine, Growth, National Health Service, GLOBE, London, Company, Paradigm, IV, Half-life, Service, Innovation, Pharma, European Medicines Agency, Program, DMT, Lists of diseases, Contract research organization, Population, Patient, MHRA, Psychedelic drug, Industry, LSA, Safety, IPO, Development, CEO, Pharmaceutical industry, Medical device, Takeda

LONDON, May 25, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, provides a business update ahead of its annual financial results for the fiscal year ended February 28, 2022. All references to “$” in this press release refer to Canadian dollars unless otherwise indicated.

Key Points: 
  • LONDON, May 25, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the Company or Small Pharma), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, provides a business update ahead of its annual financial results for the fiscal year ended February 28, 2022.
  • Small Pharma has appointed Dr. Alastair Riddell as Chief Operating Officer of the Company.
  • Dr. Riddell is a highly respected leader with vast experience across the healthcare industry and we are delighted to welcome him to the team at Small Pharma.
  • The Companys annual financial results for the fiscal year ended February 28, 2022 will be reported in June 2022.

Instem to Release Next Edition of its Leading Computational Toxicology Software Suite

Retrieved on: 
Thursday, July 29, 2021
Research, Technology, Software, Biotechnology, Managed care, General Health, Health, Data management, Science, Other Science, Activation, Alert messaging, Institute for Stem Cell Science and Regenerative Medicine

Clients can also access well over 500,000 toxicology studies for more than 200,000 chemicals, enabling fast, accurate, defendable and regulatory-accepted predictions.

Key Points: 
  • Clients can also access well over 500,000 toxicology studies for more than 200,000 chemicals, enabling fast, accurate, defendable and regulatory-accepted predictions.
  • New Bioactivation Profiler This brand new, first-to-market Bioactivation Alerts suite includes a series of structural alerts associated with reactive metabolite formation.
  • Instem will be conducting a comprehensive program to help raise awareness of this important 2021 software release through on-demand demonstrations and at key industry events.
  • Instem supports its global roster of clients through offices in the United States, United Kingdom, France, Japan, China, and India.

Instem Acquires Market Leader d-wise to Further Accelerate Life Science Development

Retrieved on: 
Monday, March 22, 2021
Research, Technology, Clinical trials, Software, Biotechnology, General Health, Pharmaceutical, Health, Data management, Science, Institute for Stem Cell Science and Regenerative Medicine, Stem cell research, Institutes

More than a growth-based acquisition, this can truly help transform the industry landscape, states Phil Reason, CEO at Instem.

Key Points: 
  • More than a growth-based acquisition, this can truly help transform the industry landscape, states Phil Reason, CEO at Instem.
  • By providing solutions across a wide area of the life science R&D continuum, Im certain that as part of Instem we will accelerate clinical development timelines and have an even broader impact on human health and wellbeing.
  • A global provider of leading software solutions and scientific insight services, Instem is helping clients bring their life enhancing products to market faster.
  • Across the entire drug development value chain, every day Instem solutions are meeting the rapidly expanding needs of life science organizations for data-driven decision making, leading to safer, more effective products.